HISTORICAL FACTS: Citius pharmaceuticals - Caught on Camera

Citius Pharmaceuticals (CTXR) Earnings Watch: Pharma Stock Signals for Investors

Citius Pharmaceuticals (CTXR) has been making significant progress in its pipeline, garnering investors' attention. However, considering that CTXR is an unprofitable and pre-revenue business, is it worth investing now as the company prepares to report quarterly results? Keep reading.

StockNews.com · Dec 11, 2023

First Patient Dosed in Citius Pharma's Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced enrolment of first patient in the Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids. 

Benzinga · Apr 26, 2022

Citius Pharmaceuticals: Q1 Earnings Insights

Citius Pharmaceuticals (NASDAQ:CTXR) reported its Q1 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Citius Pharmaceuticals reported in-line EPS of $-0.06 versus an estimate of $-0.06.

Benzinga · Feb 10, 2022